Ignite Creation Date:
2025-12-24 @ 10:55 PM
Ignite Modification Date:
2025-12-25 @ 8:23 PM
Study NCT ID:
NCT06138769
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-07-03
First Post:
2023-11-14
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma
Sponsor:
Asan Medical Center
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
LENVINEXT
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |
| None | OTHER | View |